Assura picks KKR consortium bid over rival PHP proposal

Assura Group's board has recommended a final £1.7 billion takeover offer from a KKR and Stonepeak consortium, valuing shares at 52.1p including dividends, a 39.2% premium to the pre-offer price. The decision rejects a rival proposal from Primary Health Properties PLC due to concerns about over-leverage and uncertainty surrounding asset disposals. The KKR/Stonepeak offer, proceeding via takeover, offers increased certainty with antitrust clearances already secured in multiple regions.

Analysis

Assura Group's board has formally recommended a £1.7 billion final cash takeover offer from a consortium comprising KKR and Stonepeak, valuing Assura shares at 52.1p each, inclusive of two 0.84p dividends. This offer represents a substantial 39.2% premium to Assura's pre-offer share price, signalling a strong valuation for existing shareholders. Crucially, this decision follows a period of due diligence where an alternative proposal from Primary Health Properties PLC was evaluated and ultimately rejected due to perceived "material risks and downsides," specifically citing concerns over potential over-leverage and uncertainty linked to planned asset disposals. The KKR/Stonepeak offer enhances deal certainty by proceeding as a takeover offer and having already secured antitrust clearances in key jurisdictions including China, Israel, and South Korea, which significantly de-risks the transaction timeline. The Assura board's endorsement, based on its fiduciary duty after a "careful and thorough evaluation," underscores their confidence in this offer maximizing shareholder value compared to alternatives.

Key Decisions for Investors

• Assura shareholders should favorably consider the KKR/Stonepeak cash offer of 52.1p per share, given the significant 39.2% premium, the board's unanimous recommendation, and the rejection of a riskier alternative proposal.
• Investors should appreciate the enhanced deal certainty provided by the KKR/Stonepeak offer structure and the pre-secured antitrust approvals, which reduces the likelihood of transaction failure and shortens the completion timeline.
• Considering this is a final offer from KKR/Stonepeak, and the Assura board has deemed it superior after a thorough evaluation focused on maximizing shareholder value and minimizing risks, accepting the terms appears to be a prudent course of action for shareholders seeking to realize this value.